Agios Pharm

Yahoo Finance • 8 days ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare di... Full story

Yahoo Finance • 14 days ago

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

Drugmaker Agios Pharmaceuticals(NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's the overarching takeaway from this mornin... Full story

Yahoo Finance • 14 days ago

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals(NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly $82,000 on March 5, 2026, according to an SE... Full story

Yahoo Finance • last month

How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated fair value estimate for Agios Pharmaceuticals has shifted to US$38.88 from US$36.75, while several bullish... Full story

Yahoo Finance • 2 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA f... Full story

Yahoo Finance • 4 months ago

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended trading on Tuesday after it was announced tha... Full story

Yahoo Finance • 4 months ago

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the y... Full story

Yahoo Finance • 4 months ago

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) rem... Full story

Yahoo Finance • 4 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 4 months ago

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight

DelveInsight Business Research LLP The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug developme... Full story

Yahoo Finance • 5 months ago

Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price tar... Full story

Yahoo Finance • 5 months ago

Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX) (SPY) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +0.56%.  December E-mini S&P futures (ESZ25) rose +0.39... Full story

Yahoo Finance • 5 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Stocks Supported by Strength in Megacap Tech and Chip Stocks

The S&P 500 Index ($SPX) (SPY) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.22%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.74%.  December E-mini S&P futures (ESZ25) are up +0.39%, and December... Full story

Yahoo Finance • 5 months ago

Oversold Conditions For Agios Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 5 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in pr... Full story

Yahoo Finance • 5 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 5 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

$12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RIS... Full story

Yahoo Finance • 5 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Altria Group (MO [https://seekingalpha.com/symbol/MO]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Enterprise Products Partners L.P. (EPD [https://seekin... Full story

Yahoo Finance • 6 months ago

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story